February 15, 2017 10:03 AM ESTUpdated 10:44 AM
News Briefing

Io­n­is bags a $75M mile­stone from Bay­er; In­ven­ti­va gar­ners $51M from IPO

Shehla Shakoor

Managing Director

• Io­n­is Phar­ma­ceu­ti­cals $IONS is pick­ing up a $75 mil­lion mile­stone pay­ment from Bay­er re­lat­ed to IO­N­IS-FXIRx. Io­n­is plans to start a Phase IIb …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times